TargetMol

Droxidopa

Product Code:
 
TAR-T2547
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2547-1mL1 mL * 10 mM (in DMSO)£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2547-5mg5mg£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2547-10mg10mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2547-25mg25mg£198.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2547-50mg50mg£250.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2547-100mg100mg£357.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Droxidopa is an orally available prodrug of norepinephrine that is used in the treatment of symptomatic orthostatic hypotension due to neurogenic causes of autonomic failure.
CAS:
23651-95-8
Formula:
C9H11NO5
Molecular Weight:
213.189
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9966
SMILES:
N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O
Target:
Adrenergic Receptor

References

1. Mathias CJ. Clin Auton Res, 2008, 18 Suppl 1, 25-29. 2. Mathias CJ, et al. Clin Auton Res, 2001, 11(4), 235-242. 3. Kaufmann H. Clin Auton Res, 2008, 18 Suppl 1, 19-24. 4. Goldstein DS. Cardiovasc Drug Rev, 2006, 24(3-4), 189-203.